

Application No.: 10/811,296


2

Docket No.: 03108/0201072-US0

This listing of claims will replace all prior versions, and list.ings, of claims in the application:

Listing of Claims:

1. (Original) N-aryloxypropanoyl-N'-phenethyl urea of general formula 3 wherein R is selected from the group consisting of H, 2, 3 or 4-trifluoromethyl, 2, 3, or 4-chloro, 2, 3, c · 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl and 4-formyl and X is S or O.



Formula 3

2. (Original) A compound of formula 3 as claimed in claim 1 selected from the group consisting of.:

3a. N-[2-hydroxy-3-(4-trifluoromethylphenoxy)propyl]-N'-2-phenethyl-urea.

3b. N-[2-hydroxy-3-phenoxypropyl]-N'-2-phenethyl-urea

3c. N-[2-hydroxy-3-(3-trifluoromethylphenoxy)propyl]-N'-2-phenethyl-urea

3d. N-[3-(4-chlorophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea

3e. N-[3-[4-bromophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea

3f. N-[3-(4-acetylphenoxy)- 2-hydroxypropyl]-N'-2-phenethyl-urea

3g. N-[2-hydroxy-3-(4-propionylphenoxy)propyl]-N'-2-phenethyl-urea

3h. N-[3-(4-acetamidophenoxy)- 2-hydroxypropyl]-N'-2-phenethyl-urea

{W:\03108\0201072us0\00366241.DOC \* 031080201072US0 \* }

Application No.: 10/811,296

3

Docket No.: 03108/0201072-US0

3i. N-[2-hydroxy-3(2-methoxyphenoxy)propyl]-N'-2-phenethyl-urea

3j. N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-N'-2-phenethyl-urea

3k. N-[3-(4-cyanophenoxy)-2-hydroxypropyl]-N'-2-phenethyl-urea

3l. N-[2-hydroxy-3-(2-methylphenoxy)propyl]-N'-2-phenethyl-urea


3m. N-[2-hydroxy-3-(3-methoxyphenoxy)propyl]-N'-2-phenethyl-urea

3n. N-[2-hydroxy-3-(4-trifluoromethylphenoxy)propyl]-N'-2-phenethyl-thiourea

3o. N-[2-hydroxy-3-(4-propionylphenoxy)propyl]-N'-2-phenethyl-thiourea

3p. N-[2-hydroxy-3-(4-methoxyphenoxy)propyl]-N'-2-phenethyl-thiourea

**3** 3. (Original) A process for the preparation of N-aryloxypropanolyl-N'-phenethyl urea derivatives of the formula 3



Formula 3

wherein X is S or O and R is selected from the group consisting of H, 2, 3 or 4-trifluoromethyl, 2,3, or 4-chloro, 2, 3, or 4-bromo, 4-acetyl, 4-propionyl, 4-acetamido, 2,3 or 4 methoxy, 4 nitrile, 2,3 or 4-methyl and 4-formyl,


the process comprising reacting a substituted phenolic compound with epichlorohydrin in the presence of alkali carbonate to obtain the corresponding phenoxy epoxy propane which is then reacted with ammonium hydroxide to obtain aminoalcohol of formula 1

{W:\03108\0201072us0\00366241.DOC \*031080201072US0\* }

Application No.: 10/811,296


4

Docket No.: 03108/0201072-US0



Formula 1

wherein R is given above, which is then reacted with a cyanate compound of formula 2 wherein is oxygen or sulphur



Formula 2

to obtain the compound of formula 3.

*4.* (Previously presented) The process as claimed in claim 3 wherein the alkali carbonate is selected from K<sub>2</sub>CO<sub>3</sub> and Na<sub>2</sub>CO<sub>3</sub>.

*5.* (Previously presented) The process as claimed in claim 3 wherein the reaction between compound of formula 1 and compound of formula 2 is carried out in an aprotic solvent selected from the group consisting of CH<sub>3</sub>CN, CHCl<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, THF and 1,2-Dichloroethane.

*6.* (Previously presented) The process as claimed in claim 3 wherein the reaction between compound of formula 1 and compound of formula 2 is carried out at a temperature in the range of 15-50°C for a period ranging between 5-18 hrs.

*7.* (Previously presented) The process as claimed in claim 3 wherein the reaction between the compound of formula 1 and compound of formula 2 is carried out in equimolar proportions of compound 1 and compound 2.

(W:\03108\0201072\us0\00366241.DOC \*031080201072US0\*)

Application No.: 10/811,296

5

Docket No.: 03108/0201072-US0

8. (Currently amended) A pharmaceutical composition comprising a compound of formula 3 of claim 1 claim 2 with one or more conventional additives.

9. (Currently amended) A method for the treatment of obesity comprising administering to a subject suffering from obesity, a pharmaceutically effective amount of a compound of formula 3 of claim 1 claim 2.

10. (Previously presented) The method as claimed in claim 9 wherein the compound of formula 3 is administered in the form of a pharmaceutical composition of compound of formula 3 with pharmaceutically acceptable additives.

11. (Previously presented) The method as claimed in claim 9 wherein the compound of formula 3 is administered alone or with one or more pharmaceutically acceptable excipients.

12  
13. (Currently amended) The method as claimed in claim 16-14 wherein N-[2-hydroxy-3-(4-trifluoromethylphenoxy)propyl]-N'-2-phenethylurea (3a) shows same activity as Sibutramine.

14. (Currently amended) The method as claimed in claim 16-14 wherein (N-[2-hydroxy-3-(4-trifluoromethylphenoxy) propyl]-N'-2-phenethyl-urea, showed a decrease of 41.42% in food intake as compared to food intake in the control group.

15. (Currently amended) The method as claimed in claim 16-14 wherein (N-[2-hydroxy-3-(4-methoxyphenoxy) propyl]-N'-2-phenethyl-urea (compound 3j), showed decrease of 3 .82% in food intake as compared to food intake in the control group.

16. (Currently amended) The method as claimed in claim 16-14 wherein (N-[2-hydroxy-3-(4-trifluoromethylphenoxy)propyl]-N'-2-phenethyl-thiourea (compound 3n), showed decrease of 28.4% in food intake as compared to food intake in the control group.

17. (New) A method for the treatment of obesity comprising administering to a subject suffering from obesity, a pharmaceutically effective amount of a compound of claim 2.

{W:\03108\0201072us0\00366241.DOC \*031080201072US0\*}